Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request, 41554-41555 [2016-15092]
Download as PDF
<![CDATA[
41554
Federal Register / Vol. 81, No. 123 / Monday, June 27, 2016 / Notices
mstockstill on DSK3G9T082PROD with NOTICES
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2013–D–1170 for ‘‘Chronic Hepatitis C
Virus Infection: Developing DirectActing Antiviral Drugs for Treatment;
Draft Guidance for Industry.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on https://
www.regulations.gov. Submit both
VerDate Sep<11>2014
18:52 Jun 24, 2016
Jkt 238001
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Jeffrey Murray, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 6360,
Silver Spring, MD 20993–0002, 301–
796–1500.
In the
Federal Register of May 4, 2016 (81 FR
26805), FDA published a notice of
availability.
Interested persons were originally
given until July 5, 2016, to comment on
the draft guidance for industry entitled
‘‘Chronic Hepatitis C Virus Infection:
Developing Direct-Acting Antiviral
Drugs for Treatment.’’
From July 1 through July 5, 2016, the
Federal eRulemaking Portal, https://
www.regulations.gov, is undergoing
maintenance. We are, therefore,
extending the comment period for the
draft guidance for industry entitled
‘‘Chronic Hepatitis C Virus Infection:
Developing Direct-Acting Antiviral
Drugs for Treatment.’’ The extended
comment period will close on July 19,
2016.
SUPPLEMENTARY INFORMATION:
Dated: June 21, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–15098 Filed 6–24–16; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission to OMB for
Review and Approval; Public Comment
Request
Health Resources and Services
Administration, HHS.
ACTION: Notice.
AGENCY:
In compliance with section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the Health
Resources and Services Administration
(HRSA) has submitted an Information
Collection Request (ICR) to the Office of
Management and Budget (OMB) for
review and approval. Comments
submitted during the first public review
of this ICR will be provided to OMB.
OMB will accept further comments from
the public during the review and
approval period.
DATES: Comments on this ICR should be
received no later than July 27, 2016.
ADDRESSES: Submit your comments,
including the ICR Title, to the desk
officer for HRSA, either by email to
OIRA_submission@omb.eop.gov or by
fax to 202–395–5806.
FOR FURTHER INFORMATION CONTACT: To
request a copy of the clearance requests
submitted to OMB for review, email the
HRSA Information Collection Clearance
Officer at paperwork@hrsa.gov or call
(301) 443–1984.
SUPPLEMENTARY INFORMATION:
Information Collection Request Title:
Black Lung Clinics Program
Performance Measures OMB No. 0915–
0292–Extension
Abstract: HRSA’s Federal Office of
Rural Health Policy (FORHP), conducts
an annual data collection of information
for the Black Lung Clinics Program,
which has been ongoing with OMB
approval since 2004. The Black Lung
Clinics Program seeks to reduce the
morbidity and mortality associated with
occupationally-related coal mine dust
lung disease. Collecting this data
provides HRSA with information on the
extent to which each grantee is meeting
the needs of these miners in their
communities.
Need and Proposed Use of the
Information: Data from the annual
report provides quantitative information
about the clinics, specifically: (a) The
characteristics of the patients they serve
(gender, age, disability level, occupation
type); (b) the characteristics of services
provided (medical encounters, nonmedical encounters, benefits
SUMMARY:
E:\FR\FM\27JNN1.SGM
27JNN1
41555
Federal Register / Vol. 81, No. 123 / Monday, June 27, 2016 / Notices
counseling, and outreach); and, (c) the
number of patients served. This
assessment enables HRSA to provide
data required by Congress under the
Government Performance and Results
Act of 1993. It also ensures that funds
are effectively used to provide services
that meet the target population needs.
HRSA does not plan to make any
changes to the performance measures at
this time.
Likely Respondents: Black Lung
Clinics Program Grantees.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
respondents
Form name
Number of
responses per
respondent
Total
responses
Average
burden per
response
(in hours)
Total burden
hours
Black Lung Clinics Program Measures ...............................
15
1
15
10
150
Total ..............................................................................
15
........................
15
........................
150
Jason E. Bennett,
Director, Division of the Executive Secretariat.
Officer at paperwork@hrsa.gov or call
(301) 443–1984.
[FR Doc. 2016–15092 Filed 6–24–16; 8:45 am]
SUPPLEMENTARY INFORMATION:
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission to OMB for
Review and Approval; Public Comment
Request
Health Resources and Services
Administration, HHS.
ACTION: Notice.
AGENCY:
In compliance with section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the Health
Resources and Services Administration
(HRSA) has submitted an Information
Collection Request (ICR) to the Office of
Management and Budget (OMB) for
review and approval. Comments
submitted during the first public review
of this ICR will be provided to OMB.
OMB will accept further comments from
the public during the review and
approval period.
DATES: Comments on this ICR should be
received no later than July 27, 2016.
ADDRESSES: Submit your comments,
including the ICR Title, to the desk
officer for HRSA, either by email to
OIRA_submission@omb.eop.gov or by
fax to 202–395–5806.
FOR FURTHER INFORMATION CONTACT: To
request a copy of the clearance requests
submitted to OMB for review, email the
HRSA Information Collection Clearance
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:52 Jun 24, 2016
Jkt 238001
Information Collection Request Title:
Sickle Cell Disease Treatment
Demonstration Program—Quality
Improvement Data Collection.
OMB No.: 0906–xxxx–NEW.
Abstract: In response to the growing
need for resources and coordination of
resources devoted to sickle cell disease
and other hemoglobinopathies, the
United States Congress, under Section
712 of the American Jobs Creation Act
of 2004 (Pub. L. 108–357) (42 U.S.C.
300b–1 note), authorized a
demonstration program for the
prevention and treatment of sickle cell
disease (SCD) to be administered by
HRSA’s Maternal and Child Health
Bureau (MCHB) in the U.S. Department
of Health and Human Services. The
program is known as the Sickle Cell
Disease Treatment Demonstration
Program (SCDTDP). The SCDTDP is
designed to improve access to services
for individuals with sickle cell disease,
improve and expand patient and
provider education, and improve and
expand the continuity and coordination
of service delivery for individuals with
sickle cell disease and sickle cell trait.
The specific aims for the program are
threefold: (1) Increase the number of
providers treating persons with sickle
cell disease, (2) increase the number of
providers using evidence-based
treatments in sickle cell disease, such as
prescribing hydroxyurea, and (3)
increase the number of providers
knowledgeable about treating sickle cell
disease and the number of sickle cell
patients that are seen by providers
knowledgeable about sickle cell disease.
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
To achieve the goals and objectives of
the program, the SCDTDP uses quality
improvement (QI) methods in a
collective impact model which supports
cross-sector collaboration for achieving
measurable effects on major social
issues. The collective impact model
requires shared measurement which
facilitates tracking progress in a
standardized method to promote
learning and enhance continuous
improvement.
Need and Proposed Use of the
Information: The purpose of the
proposed data collection strategy is to
implement a system to monitor the
progress of MCHB-funded activities in
improving care and health outcomes for
individuals living with sickle cell
disease/trait and meeting the goals of
the SCDTDP. Each regional grantee site
will be asked to report on a core set of
evidence-based measures related to
healthcare utilization among
individuals with sickle cell disease and
the quality of care of the SCD
population.
The data collected for the SCDTDP
will consist of administrative medical
claims data collected from State
Medicaid Programs and Medicaid
Managed Care Organizations that
administer Medicaid on behalf of states.
The data is collected either for or by
State Medicaid offices for delivery of
services subject to Medicaid
reimbursement.
The data collection strategy will
provide an effective and efficient
mechanism to do the following: (1)
Assess the improvements in access to
care for sickle cell patients provided by
activities in the SCDTDP; (2) collect,
coordinate, and distribute data, best
practices, and findings from regional
grantee sites to drive improvement on
E:\FR\FM\27JNN1.SGM
27JNN1
]]>Agencies
[Federal Register Volume 81, Number 123 (Monday, June 27, 2016)]
[Notices]
[Pages 41554-41555]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-15092]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Agency Information Collection Activities: Submission to OMB for
Review and Approval; Public Comment Request
AGENCY: Health Resources and Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the Health Resources and Services Administration
(HRSA) has submitted an Information Collection Request (ICR) to the
Office of Management and Budget (OMB) for review and approval. Comments
submitted during the first public review of this ICR will be provided
to OMB. OMB will accept further comments from the public during the
review and approval period.
DATES: Comments on this ICR should be received no later than July 27,
2016.
ADDRESSES: Submit your comments, including the ICR Title, to the desk
officer for HRSA, either by email to OIRA_submission@omb.eop.gov or by
fax to 202-395-5806.
FOR FURTHER INFORMATION CONTACT: To request a copy of the clearance
requests submitted to OMB for review, email the HRSA Information
Collection Clearance Officer at paperwork@hrsa.gov or call (301) 443-
1984.
SUPPLEMENTARY INFORMATION:
Information Collection Request Title: Black Lung Clinics Program
Performance Measures OMB No. 0915-0292-Extension
Abstract: HRSA's Federal Office of Rural Health Policy (FORHP),
conducts an annual data collection of information for the Black Lung
Clinics Program, which has been ongoing with OMB approval since 2004.
The Black Lung Clinics Program seeks to reduce the morbidity and
mortality associated with occupationally-related coal mine dust lung
disease. Collecting this data provides HRSA with information on the
extent to which each grantee is meeting the needs of these miners in
their communities.
Need and Proposed Use of the Information: Data from the annual
report provides quantitative information about the clinics,
specifically: (a) The characteristics of the patients they serve
(gender, age, disability level, occupation type); (b) the
characteristics of services provided (medical encounters, non-medical
encounters, benefits
[[Page 41555]]
counseling, and outreach); and, (c) the number of patients served. This
assessment enables HRSA to provide data required by Congress under the
Government Performance and Results Act of 1993. It also ensures that
funds are effectively used to provide services that meet the target
population needs. HRSA does not plan to make any changes to the
performance measures at this time.
Likely Respondents: Black Lung Clinics Program Grantees.
Burden Statement: Burden in this context means the time expended by
persons to generate, maintain, retain, disclose or provide the
information requested. This includes the time needed to review
instructions; to develop, acquire, install and utilize technology and
systems for the purpose of collecting, validating and verifying
information, processing and maintaining information, and disclosing and
providing information; to train personnel and to be able to respond to
a collection of information; to search data sources; to complete and
review the collection of information; and to transmit or otherwise
disclose the information. The total annual burden hours estimated for
this ICR are summarized in the table below.
Total Estimated Annualized Burden--Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Form name Number of responses per Total per response Total burden
respondents respondent responses (in hours) hours
----------------------------------------------------------------------------------------------------------------
Black Lung Clinics Program 15 1 15 10 150
Measures.......................
-------------------------------------------------------------------------------
Total....................... 15 .............. 15 .............. 150
----------------------------------------------------------------------------------------------------------------
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2016-15092 Filed 6-24-16; 8:45 am]
BILLING CODE 4165-15-P
